A Ball Ground-based manufacturer of medical oxygen supply equipment has acquired a California-based maker of testing equipment used in the diagnosis of asthma, company officials announced Wednesday.
CAIRE, Inc. announced it has acquired Spirosure, which will become a new division of called CAIRE Diagnostics, company officials said. Spirosure will continue to operate at its facility in Pleasanton, California, CAIRE Vice President Barry Hassett said.
Spirosure developed and manufactures a machine to test for fractional exhaled nitric oxide, which is an indicator of allergic inflammation in people with asthma.
“We are pleased to add Spirosure’s technology to our market-leading oxygen solution portfolio. (Exhaled nitric oxide) is quickly becoming recognized by the clinical community as an important diagnostic and management tool for clinicians who treat asthma patients,” said Earl Lawson, CAIRE president and CEO. “The acquisition of Spirosure further diversifies our portfolio and provides access to the $5 billion respiratory diagnostic sector, a market segment where we anticipate rapid growth and adoption.”
Spirosure’s top executive said his team is eager to become part of CAIRE.
“We are very pleased to have found an excellent strategic buyer in CAIRE through one of our key investors,” said Solomon Ssenyange, CEO and chairman of Spirosure. “CAIRE shares our commitment to technological leadership and, with its large international organization, is well-positioned to realize the full potential of our proprietary technology both commercially and with regard to our development pipeline. We look forward to an exciting future as part of CAIRE.”
CAIRE manufactures portable and stationary oxygen therapy devices and turnkey on-site generation equipment. The products support home care, hospice, long-term care, hospitals, military, and industrial applications. The company was acquired in 2018 by Nagoya, Japan-based NGK Spark Plug Co., LTD. NGK had previously invested in Spirosure, CAIRE officials said.